Prosecution Insights
Last updated: November 11, 2026
Application No. 18/027,291

DEFORMABLE PRE-PACKAGED DEVICE FOR INJECTING A LIQUID

Non-Final OA §102§103§112
Filed
Mar 20, 2023
Priority
Sep 21, 2020 — IT 102020000022168 +1 more
Examiner
PATEL, SHEFALI DILIP
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Orofino Pharmaceuticals Group S R L
OA Round
3 (Non-Final)
58%
Grant Probability
Moderate
3-4
OA Rounds
2m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
440 granted / 756 resolved
-11.8% vs TC avg
Strong +28% interview lift
Without
With
+27.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
54 currently pending
Career history
830
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
42.6%
+2.6% vs TC avg
§102
21.4%
-18.6% vs TC avg
§112
29.1%
-10.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 756 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 24, 2026, has been entered. Acknowledgments In the reply, filed on June 24, 2026, Applicant requested the consideration of the amendment of May 26, 2026. The amendment is now considered. Applicant amended claims 1, 8, and 12. In the final rejection of March 26, 2026, Examiner objected to claim 8. Applicant amended claim 8. Objection is withdrawn. Examiner rejected claims 1-11 under 35 U.S.C. 112(a). Applicant amended claims 1 and 8. Rejection is withdrawn. Examiner rejected claim 12 under 35 U.S.C. 112(b). Applicant amended claim 12. Rejection is withdrawn. Claim Objections Claims 1 and 12 are objected to because of the following informalities: In regards to claim 1, line 7, “said second containment chambers chamber” should be changed to “said second containment chamber”. In regards to claim 1, line 13, “the first lower surfaces surface” should be changed to “the first lower surface”. In regards to claim 1, line 16, “therebetween between” should be changed to “between”. In regards to claim 1, line 20, “the second lower surfaces surface” should be changed to “the second lower surface”. In regards to claim 1, line 23, “therebetween between” should be changed to “between”. In regards to claim 12, line 2, “ejecting injecting” should be changed to “injecting”. In regards to claim 12, line 10, “said second containment chambers chamber” should be changed to “said second containment chamber”. In regards to claim 12, line 16, “the first lower surfaces surface” should be changed to “the first lower surface”. In regards to claim 12, lines 19-20, “therebetween between” should be changed to “between”. In regards to claim 12, line 24, “the second lower surfaces surface” should be changed to “the second lower surface”. In regards to claim 12, line 28, “therebetween between” should be changed to “between”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 8-11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In regards to claim 8, line 4 recites: "as individually defined in claim 1". First, this limitation does not follow dependent claim construction referring back to "the device of claim 1". Second, it is unclear which components are "individually defined in claim 1". Claims 9-11 are rejected by virtue of being dependent upon claim 8. In regards to claim 8, line 12 recites: "the second containment chamber according to claim 1". First, this limitation does not follow dependent claim construction referring back to "the device of claim 1". Second, claim 8, line 4 already recited back to claim 1 reciting "as individually defined in claim 1". Claims 9-11 are rejected by virtue of being dependent upon claim 8. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 4-11 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Genosar (US 2014/0066846). In regards to claim 1, Genosar teaches a device (Figures 5a-6e) for injecting a reconstitutable liquid mixture, the device comprising: a first containment chamber (57) for a first component (first substance) of the reconstitutable liquid mixture a second containment chamber (51) for a second component (second substance) of the reconstitutable liquid mixture first mechanical and fluidic connection means (52) between said first containment chamber and said second containment chambers chamber second mechanical and fluidic connection means (14) between said second containment chamber and an injection needle (22) wherein: said first containment chamber comprises, along a mixture injection direction, a first upper surface and a first lower surface in a shape of a cone or a truncated cone, the first upper surface and the first lower surfaces surface having a same axis of symmetry and being connected along a common base circumference (Figures 5a, 6a) said first upper surface and said first lower surface extend in opposite directions along and around said axis of symmetry and form a non-zero angle β therebetween between said first upper surface and said first lower surface at the common base circumference (Figures 5a, 6a) said second containment chamber comprises, along said mixture injection direction, a second upper surface and a second lower surface in a shape of a cone or a truncated cone, the second upper surface and the second lower surfaces surface having said axis of symmetry and being connected along a common base circumference (Figures 5a-6b) said second upper surface and said second lower surface extend in opposite directions along and around said axis of symmetry and form a non-zero angle α therebetween between said second upper surface and said second lower surface at the common base circumference of said second upper surface and said second lower surface (Figures 5a-6b) wherein said first lower surface and said second lower surface are separately deformable by compression against said first upper surface and said second upper surface, respectively (Figures 6a-6c) wherein: said first mechanical and fluidic connection means comprise an outlet neck (proximal portion of 52) of said first containment chamber and an inlet neck (distal portion of 52) of said second containment chamber connected to form a single fluidic connection duct (52) said single fluidic connection duct is configured to keep said first lower surface and said second lower surface at a distance configured to be larger than a section of a finger (Figures 5a-6b) In regards to claim 4, Genosar teaches wherein said first upper surface and said first lower surface are formed in one piece (Figures 5a, 6a). In regards to claim 5, Genosar teaches wherein said second upper surface and said second lower surface are formed in one piece (Figures 5a-6b). In regards to claim 6, Genosar teaches wherein said first lower surface and said second lower surface are made of an inelastically deformable material (Figures 5a-6c)(paragraph [0006]). In regards to claim 7, though Genosar does not state “wherein said inelastically deformable material allows a total crushing of said first lower surface and said second lower surface against said first upper surface and said second upper surface, respectively”, it would be understood that said inelastically deformable material (paragraph [0006]: olefin polymers), disclosed by Genosar, would be capable of total crushing of said first lower surface and said second lower surface against said first upper surface and said second upper surface, respectively, as olefin polymers are crushable materials. In regards to claim 8, Genosar teaches an injection kit (Figures 5a-6e) for injecting a reconstitutable liquid mixture, comprising: a first containment chamber (57) and a second containment chamber (51), separate from the first containment chamber, as individually defined in claim 1 wherein each of said first containment chamber and said second containment chamber respectively comprises an upper surface and a lower surface in a shape of a cone or a truncated cone connected along a common base circumference (Figures 5a, 6a), said lower surface of each of said first containment chamber and said second containment chamber being deformable by compression against said upper surface of each of said first containment chamber and said second containment chamber, respectively (Figures 6a-6c) first mechanical and fluidic connection means (52) between the first containment chamber and the second containment chamber according to claim 1, wherein an outlet neck (proximal portion of 52) of said first containment chamber and an inlet neck (distal portion of 52) of said second containment chamber, which are configured to connect and form a single fluidic connection duct (52) second mechanical and fluidic connection means (14) between said second containment chamber and an injection needle (22) said injection needle being connectable to said second containment chamber by said second mechanical and fluidic connection means (Figures 5a-6c) In regards to claim 9, Genosar teaches wherein said outlet neck of said first containment chamber and the inlet neck of said second containment chamber each comprise a removable or breakable or openable watertight closing element (52) (Figures 5a-6c)(paragraph [0051]: a high barrier to… moisture). In regards to claim 10, Genosar teaches wherein the removable or breakable or openable watertight closing element is a peelable partition (52) (Figures 5a-6c). In regards to claim 11, Genosar teaches wherein said second mechanical and fluidic connection means comprise a removable watertight closing element (14) (Figures 5a-6d)(paragraph [0051]: a high barrier to… moisture). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 2 is rejected under 35 U.S.C. 103 as being unpatentable over Genosar, as applied to claim 1 above, and further in view of Steiner (US 3,892,237). In regards to claim 2, Genosar is silent about wherein said first mechanical and fluidic connection means comprise a filter and/or a valve. Steiner teaches a device (Figures 1-4) wherein a first mechanical and fluidic connection means comprise a filter (33). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to modify said first mechanical and fluidic connection means, of the device of Genosar, to comprise a filter, as taught by Steiner, as such will prevent splits of the first containment chamber from being carried on into the second containment chamber (column 1, line 68, to column 2, lines 1-5). Claim 3 is rejected under 35 U.S.C. 103 as being unpatentable over Genosar, as applied to claim 1 above, and further in view of Tsukada (WO 2012/056524). In regards to claim 3, Genosar is silent about wherein said first mechanical and fluidic connection means comprise a valve adapted to allow a one-way flow of said first component of the reconstitutable liquid mixture. Tsukada teaches a device (Figure 1) wherein a first mechanical and fluidic connection means comprise a valve (check valve) adapted to allow a one-way flow of a first component of a reconstitutable liquid mixture (paragraphs [Separation part]). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to modify said first mechanical and fluidic connection means, of the device of Genosar, to comprise a valve, as taught by Tsukada, as such will allow only the flow of a soft substance from the first containment chamber to the second containment chamber (paragraphs [Separation part]) in order to prevent unnecessary backward flow of liquid. Claim 12 is rejected under 35 U.S.C. 103 as being unpatentable over Genosar, and further in view of Kwiatkowski et al (US 5,609,580). In regards to claim 12, Genosar teaches a method (Figures 6a-6e) for reconstituting a reconstitutable liquid mixture and ejecting injecting the reconstitutable liquid mixture from an injection needle (22), the method comprising: providing a device (Figures 5a-6e) for injecting the reconstitutable liquid mixture, the device comprising: a first containment chamber (57) for a first component (first substance) of the reconstitutable liquid mixture a second containment chamber (51) for a second component (second substance) of the reconstitutable liquid mixture first mechanical and fluidic connection means (52) between said first containment chamber and said second containment chambers chamber second mechanical and fluidic connection means (14) between said second containment chamber and the injection needle wherein: said first containment chamber comprises, along a mixture injection direction, a first upper surface and a first lower surface in a shape of a cone or a truncated cone, the first upper surface and the first lower surfaces surface having a same axis of symmetry and being connected along a common base circumference (Figures 5a, 6a) said first upper surface and said first lower surface extend in opposite directions along and around said axis of symmetry and form a non-zero angle β therebetween between said first upper surface and said first lower surface at the common base circumference (Figures 5a, 6a) said second containment chamber comprises, along said mixture injection direction, a second upper surface and a second lower surface in a shape of a cone or a truncated cone, the second upper surface and the second lower surfaces surface having said axis of symmetry and being connected along a common base circumference (Figures 5a-6b) said second upper surface and said second lower surface extend in opposite directions along and around said axis of symmetry and form a non-zero angle α therebetween between said second upper surface and said second lower surface at the common base circumference of said second upper surface and said second lower surface (Figures 5a-6b) said first lower surface and said second lower surface are separately deformable by compression (Figures 6a-6c) wherein: said first mechanical and fluidic connection means comprise an outlet neck (proximal portion of 52) of said first containment chamber and an inlet neck (distal portion of 52) of said second containment chamber connected to form a single fluidic connection duct (52) said single fluidic connection duct is configured to keep said first lower surface and said second lower surface at a distance configured to be larger than a section of a finger (Figures 5a-6b) positioning two fingers on said first upper surface and a thumb against said first lower surface (paragraph [0057]) positioning the two fingers on said second upper surface and the thumb against said first lower surface (paragraph [0057]) Genosar does not teach crushing said first lower surface against said first upper surface bringing the thumb closer to the two fingers on said first upper surface, as Genosar instead teaches pushing a plunger 25 through a proximal pinched section 15, defining the first lower surface, causing a seal to rupture and for the pinched section to restore its tubular shape bringing the thumb closer to the two fingers on said first upper surface (Figures 6a-6b)(paragraphs [0057][0059]). And Genosar does not teach crushing said second upper surface against said second lower surface bringing the thumb closer to the two fingers on said second upper surface, as Genosar instead teaches further advancing the plunger 25 such that the pressure of the first component increases causing a seal at the first mechanical and fluid connection means to rupture and for the first mechanical and fluid connection means to restore its tubular shape bringing the thumb closer to said two fingers on said second upper surface (Figures 6b-6c)(paragraphs [0057][0060]). Kwiatkowski et al teaches a method (Figures 14-17) comprising positioning two fingers on a first upper surface (of 26A) and a thumb against a first lower surface (of 26A), crushing said first lower surface against said first upper surface bringing the thumb closer to the two fingers on said first upper surface (Figures 14-15)(column 6, lines 65-67, to column 7, lines 1-4)(column 4, lines 46-54), positioning the two fingers on a second upper surface (of 28A) and the thumb against said first lower surface, and crushing said second upper surface against a second lower surface (of 28A) bringing the thumb closer to the two fingers on said second upper surface (Figure 16-17)(column 7, lines 8-12)(column 4, lines 46-54). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to modify the method, of Genosar, with crushing said first lower surface against said first upper surface bringing the thumb closer to the two fingers on said first upper surface, and crushing said second upper surface against said second lower surface bringing the thumb closer to the two fingers on said second upper surface, as taught by Kwiatkowski et al, as such will provide for a plungerless syringe providing for two stages of collapse, an initial or purge stage where air contained in the device to which the syringe is attached is purged, and a second flush stage where the remaining fluid in the syringe is expelled (column 2, lines 1-5) in order to expel or inject the fluid in a substantially bubbleless manner thereby substantially eliminating the threat of an air-embolism (column 1, lines 19-23). Response to Arguments Applicant's arguments filed May 26, 2026, have been fully considered but they are not persuasive: In regards to the claims, Applicant argued: If a skilled artisan were to remove the internal rigid plunger (25) from Genosar and apply the manual axial force of Kwiatkowski to the ends of Genosar's "thin collapsible wall", the device of Genosar would catastrophically fail. Lacking both the structural corrugations of Kwiatkowski's bellows and the internal support of its own plunger, Genosar's thin tube would suffer from severe lateral buckling. It would fold upon itself rather than generating the isolated, uniform hydraulic pressure necessary to burst the crimped seals. Consequently, applying the teaching of Kwiatkowski to Genosar would destroy Genosar's operability. As such, the proposed combination is not prima facie obvious (Remarks, page 8). Examiner disagrees. First, in regards to claims 1 and 8, based on the deletion of “without aid of a plunger”, said claims are no longer rejected under Genosar and Kwiatkowski et al. Claims 1 and 8 are now anticipated under Genosar alone. Second, in regards to claim 12, which is still rejected under Genosar and Kwiatkowski et al, Genosar shows the first containment chamber (57) and the second containment chamber (51) without internal support of the plunger 25 in Figures 5A-5B, thus being able to be modified by the crushing step teachings of Kwiatowski et al. Both Genosar and Kwiatkowski et al result in the same intended purpose of dispensing beneficial agents, such as medication, thus being reasonably combinable before the effective filing date of the claimed invention. In regards to the claims, Applicant argued: Even assuming, arguendo, that the combination were mechanically viable, the cited references still fail to disclose or suggest at least the distinguishing features of the claimed invention: "said single fluidic connection duct is configured to keep said first lower surface and said second lower surface at a distance configured to be larger than a section of a finger ". The Office maps this feature to the crimped section (52) of Genosar. However, Genosar defines this crimp (52) simply in paragraph [0057] as an "intermediate crimp 52 defining a proximal compartment 57 holding a first substance and a distal compartment 51". Because Genosar is operated by "advancing a plunger in an axial direction" (paragraph [0007]), the crimp (52) is merely a flat, pinched seal, not a defined dimensional spacer sized to accommodate a human finger… The claimed single fluidic connection duct acts as a specifically dimensioned geometric spacer. This unique structural configuration-missing entirely in Genosar and Kwiatkowski-is what physically separates the two distinct conical chambers, ensuring the user's fingers do not span both chambers simultaneously. This dimensional separation is precisely what enables the user to isolate the crushing force to each chamber independently. It is this specific geometry that successfully solves the problem of allowing a safe, two-stage manual dispensing process without buckling the entire device (Remarks, page 9). Examiner disagrees. Genosar teaches said single fluidic connection duct (52) is configured to keep said first lower surface (of 57) and said second lower surface (of 51) at a distance configured to be larger than a section of a finger (Figures 5a-6b). Finger size is variable and thus it is understood that said single fluidic connection duct (52) would be capable of accommodating a section of said variable finger size. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHEFALI D PATEL whose telephone number is (571)270-3645. The examiner can normally be reached Monday-Friday 8:30am-4:30pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kevin C Sirmons can be reached at (571) 272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SHEFALI D PATEL/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Show 2 earlier events
Dec 10, 2025
Response Filed
Mar 26, 2026
Final Rejection mailed — §102, §103, §112
May 26, 2026
Response after Non-Final Action
Jun 24, 2026
Request for Continued Examination
Jun 25, 2026
Response after Non-Final Action
Aug 10, 2026
Non-Final Rejection mailed — §102, §103, §112
Oct 30, 2026
Examiner Interview Summary
Oct 30, 2026
Applicant Interview (Telephonic)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773491
DRIP CHAMBER WITH NEEDLE VALVE
7y 0m to grant Granted Oct 27, 2026
Patent 12708706
AUXILIARY APPARATUS FOR FECAL BYPASS
3y 11m to grant Granted Aug 18, 2026
Patent 12697439
INJECTION DEVICE AND INJECTION SOLUTION TRANSFERRING SYSTEM
4y 1m to grant Granted Aug 04, 2026
Patent 12691228
AUTO-INJECTOR WITH NEEDLE COVER
5y 0m to grant Granted Jul 28, 2026
Patent 12678561
COATED SUBCUTANEOUS DEVICE AND INSERTER SYSTEM
2y 3m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
58%
Grant Probability
86%
With Interview (+27.6%)
3y 10m (~2m remaining)
Median Time to Grant
High
PTA Risk
Based on 756 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month